QEEG Studies of the Acute Effects of the Visionary Tryptamine  DMT by Acosta-Urquidi, Juan
Cosmos and History: The Journal of Natural and Social Philosophy, vol. 11, no. 2, 2015 
 
 
QEEG STUDIES OF THE ACUTE EFFECTS OF 
THE VISIONARY TRYPTAMINE DMT 
Juan Acosta-Urquidi, PhD   
 
 
ABSTRACT: Recent brain imaging studies in Psychedelic Brain Science are breaking new 
ground in our understanding of neurological substrate of biological consciousness in humans. 
The emerging field of inner experience and neuroscience is particularly well suited to the 
reexamination of the actions of psychedelics on subjective conscious experience. This approach 
is best understood as neurophenomenology. My work over the last few years has focused on the 
EEG correlates of the visionary tryptamine DMT action.  I believe the researcher must also 
have the drug experience as part of the experimental protocol, in order to fully understand the 
richness of the phenomenon. The objective of this exploratory research was to examine the 
QEEG correlates of the psychoactive smoked inhalation of exogenous DMT action.  Known as 
a potent visionary tryptamine, DMT  is ubiquitous in nature and has also been localized in the 
brain and peripheral tissues of mammals, including humans. The exact function of this 
endogenous DMT is the subject of ongoing neuropharmacological  research.  
Three sources of DMT were tested: high purity synthetic 5-MeO- DMT, Bufo 5-MeO-DMT 
(an extract from the Sonoran desert toad venom, Bufo alvarius), and N,N- DMT from a natural 
extract of the Acacia tree Mimosa hostilis  root bark. 
The DMT was delivered by smoked inhalation (vaporization). The rapid onset (10-20 sec), 
short acting  (5-15 min.), and reversible nature of the effects made such a QEEG study feasible. 
DMT dosage was adjusted to elicit an effective psychedelic experience (ca. 20-30 mg for N,N-
DMT; 2-5 mg for synthetic 5-MeO-DMT, and 30-40 mg for the Bufo 5-MeO-DMT material). 
Healthy volunteers (age 25-60; N=15 men, N=8 women) were tested.  
 The protocol consisted of:  5-10 min. baseline control (resting eyes closed) was first acquired, 
followed by the DMT test condition, usually lasting 5-15 min. When subjects recovered from 
the DMT induced altered state, a report of their subjective experience was recorded on video 
and a post recovery  EEG reading was made typically at 15-30 min. A statistical comparison 
(paired t-tests, correlated samples) of absolute power values for all EEG bands  between 
baseline vs. DMT tests and post recovery conditions was carried out for all subjects. The 
DMT- induced profound alterations in consciousness  were tracked with the shifts in the 
QEEG metrics analysed. The time course and intensity of the subjective experience correlated 
with the magnitude of the observed EEG effects.  
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The most consistent effect was a robust suppression of Alpha, obtained for both N,N-DMT and 
5-MeO-DMT (Alpha decreased ave. 72%, N=6). During recovery, some subjects showed 
Alpha rebound increased power at 15-25 min. post DMT (ave. 43% incr., P<.0107, N=9) . A 
DMT induced reversible shift in FFT spectra from Alpha to Theta was recorded in some 
subjects. Also, very signifcant hypercoherence  in all bands (especially Beta) was measured in 
most subjects.  Gamma power (35-40 Hz) was also increased in some subjects. During post 
DMT Alpha rebound, subjects reported “being in peace, a calmed state of wellbeing and 
clarity”. The significance of these findings is discussed with reference to DMT receptor 
pharmacology mechanisms  and  recent psychedelic brain imaging studies.   
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A comprehensive theory of human consciousness must account for the diversity  of 
brain states during wakefulness and sleep; including dreaming, lucid dreaming, and 
the manifestation of altered states of consciousness (ASC),  induced by endogenous and 
exogenous agents; including psychoactive drugs and psychedelics, anesthesia, hypnosis 
and the wide spectrum of mind/body practices (eg. meditation, yoga, trance, shamanic 
rituals, fasting, extreme physical challenges, ecstatic dance, sensory deprivation, 
chanting, drums, etc.). Also, from Psychiatry and Neurology must account for the 
diverse mental disorders and neuropathologies resulting from abnormal brain function 
which afflict a proportion of the human population (eg. Epilepsy, schizophrenia, 
bipolar disorders, psychosis, etc.). We must also include research into paranormal 
phenomena that can be scientifically rigorously tested (eg. Psi, ESP, telepathy, remote 
viewing, etc.) with the advent of new technologies (Radin, 2010).   
Psychedelic Brain Science, using state of the art brain imaging technology (fMRI, 
PET, SPECT, MEG, EEG) is a promising emerging field that is making breakthrough   
contributions to the understanding of the mind/brain connection. Indeed, 
psychedelics have been favored valuable tools to explore consciousness for the past 
decades, and after decades of prohibition from restrictive drug laws, Psychedelic 
Science is now experiencing a renaissance. Furthermore, these recent studies are 
breaking new ground in our understanding of the neurological substrate of biological 
consciousness in humans. The field of inner experience and neuroscience (Price, 2012) 
is an emerging epistemology particularly well suited to the examination of the actions 
of psychedelics on subjective conscious experience as a neurophenomenology of 
consciousness. 
My work over the last few years has focused on the EEG correlates of the visionary 
tryptamine DMT action.  I believe the researcher must also have the visionary drug 
experience in order to fully understand the richness of the phenomenon. 
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Humans seem to have a natural drive to explore ASC and seek ecstatic and 
transcendent experience. The use of hallucinogenic or consciousness expanding plants 
for magico/religious/spiritual activities has been a part of the human experience  for 
millennia. Archaelogical and paleoanthropological evidence points to the use of 
entheogens as far back as the Upper Paleolithic in diverse locations worldwide 
(Metzner, 2005; Shanon, 2002,2008). The sacramental use of psychoactive plants can 
bring spiritual awakening to healthy people and has the potential to offer mystical 
numinous experiences. The shamanic practices with entheogens form an impressive 
record of acquired knowledge of ASC and may contribute new insights in the 
neuroscience of consciousness (Perry, 2010). 
Psychoactive plants and preparations have been used for millennia by shamanic 
cultures in the New World and the Old World to explore spiritual realms and for 
healing purposes (Ratsch, 2005). Psychoactive plants and mushrooms also played a key 
role in Old World religions (Shanon,2002; Rush, 2013). The use of psychedelic plant 
preparations among New World tribes is far more prevalent than in the Old World. 
Of chief importance is the pan Amazonian hallucinogenic brew Ayahuasca, which is a 
preparation containing Beta carboline alkaloids (viz.Harmine, Harmaline and 
tetrahydroharmine, which act as MAOIs) contained in the vine Banisteriopsis caapi , 
which is boiled with the leafs of DMT containing plants, commonly used are Psychotria 
viridis , P. cabrerana. The DMT is orally activated by the Beta carbolines and provides 
much of the psychoactivity to the brew (Callaway,1994, 1995; McKenna, 2015). Other 
DMT containing preparations, delivered as snuffs and smoked, such as Virola and 
Cohoba, have been used in Middle America, and Caribbean and Amazonian 
shamanic cultures for centuries and continue to this day. (Ratsch, 2005).  
Ethnobotanists and phytochemists have identified at least 11 genera comprising over 75 
species of plants and fungi containing DMT ( N,N and 5-MeO-DMT) (Ratsch, 2005). 
The genus Acacia trees (New and Old world species) contains high concentrations of 
DMT. Australia has also emerged as a rich source of DMT containing Acacia tree 
species (Palmer, 2014). In the Old World, the knowledge and use of DMT containing 
Acacia species combined with the seeds of the ancient sacred plant Peganum harmala, a 
known MAOI, has been suggested as a candidate brew pharmacologically equivalent 
to Ayahuasca (Ott,1993). In the Middle East, some scholars have implicated the use of 
DMT as Biblical Entheogens (Shanon, 2008; Strassman, 2014).  In Brazil the Acacia 
tree Mimosa hostilis root bark preparation known as Jurema  has been used in shamanic 
rituals in the past which continue to this day (Ott, 1993). In recent years, Ayahuasca 
based syncretic religions (Santo Daime, UDV, Barquinia) originating in Brazil, have 
been proliferating to Europe and N. America (Metzner, 2006; Labate, 2014). This 
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rapid global expansion of contemporary neo-shamanic Ayahuasca use for spirituality 
and healing is an emerging phenomenon with complex social and legal ramifications 
(Labate, 2011). 
DMT was first synthesized in 1931 (Manske, 1931). It was then isolated from plant 
sources used by Amazonian shamans: Mimosa tenuiflora, Anadenanthera colubrina and 
Piptadenia peregrine in 1955 and its psychedelic effects were first reported in the academic 
world in 1956 (Szara, 1956). Chemically, DMT is closely related to psilocybin and 
psilocin (4-hydroxy-N-dimethyltryptamine), as well as to bufotenine (5-hydroxy-N-
dimethyltryptamine). DMT is the methylated derivative of tryptamine, the 
decarboxylated product from tryptophan. The detection of N-methyltransferase, an 
enzyme capable of converting naturally-occurring tryptamine to DMT in human 
brain was first reported in 1972 (Saavedra, 1972). Research in the 1970’s  was focused 
on linking DMT to biochemical models of schizophrenia (Wyatt,1974; Szara, 1961).  
DMT is an endogenous hallucinogen (Barker et al., 1981). It is found in the 
mammalian brain and peripheral tissues, and in humans it has been found in urine, 
blood and cerebrospinal fluid. DMT is considered an endogenous synaptic 
neuromodulator and evidence suggests that it can be locally sequestered into brain 
neurotransmitter storage vesicles. Quantitative studies measuring the abundance of 
endogenous DMT have been difficult because of its rapid metabolism (Burchett, 2006; 
Barker, 2012). DMT is known as a ligand to 5-HT receptor(s); binding to the 5-HT2A 
receptor target is believed to confer its hallucinogen properties and DMT action is 
terminated by MAO metabolism (Nichols, 2004). More recent biochemical, 
physiological, and behavioral experiments indicate that DMT is also an endogenous 
agonist regulator for the Sigma-1 receptor and inhibits voltage-gated Na channels 
(Fontanilla, 2009).   
The closely related molecule, 5-MeO-DMT has received recent scientific and 
public attention (see below). Pharmacological evidence indicates that MAOI largely 
affects 5-MeO-DMT metabolism and pharmacokinetics.  5-MeO-DMT is primarily 
inactivated through MAO-A-mediated deamination pathway. Although composite 
evidences indicate that there is likely a common site of 5-HT2A and other 5-HT2 
receptors in the central nervous system responsible for the actions of indolealkylamine 
hallucinogens, 5-MeO-DMT has been shown to act mainly through the 5-HT1A 
receptor. Thus, 5-MeO-DMT is known as a nonselective 5-HT receptor agonist, and 
both 5-HT1A and 5-HT2 receptors seem to be involved in its complex 
pharmacological and toxicological effects. (Shen, 2010) 
After decades of prohibition, DMT research was revitalized by the government 
sanctioned landmark studies exploring dose-dependent intravenous injection of N,N-
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DMT effects on human volunteers, conducted at a medical school setting by 
Strassman. These studies examined the human psychopharmacology of the DMT 
psychedelic experience (Strassman, 1994, 1996). Strassman’s groundbreaking book, 
DMT: The Spirit Molecule, published in 2001, revitalized the public’s interest in this 
visionary tryptamine which links body and spirit, and it has become a favorite of the 
psychonaut/entheogenic community. 
5-MEO-DMT  EXPERIENCE: THE “GOD MOLECULE”. 
 The 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) molecule is also a potent 
endogenous hallucinogen often coexisting with N,N-DMT in many plant species and 
also associated with a rich history of shamanic ritualistic use. It is generally accepted 
that the 5-MeO-DMT experience is qualitatively different from the N,N-DMT 
induced experience. For extraordinary descriptions of the smoked 5-MeO-DMT 
subjective transcendent experiences the reader is referred to the book Tryptamine Palace 
(Oroc, 2009). Some quotations from this book: “ I believe that what I have 
experienced is the universal state of consciousness before the knowledge of ego and 
self, a state of undifferenciated cosmic consciousness that historically William James 
described as Absolute Consciousness. This state is now commonly described among 
today’s entheogenic community as God consciousness”.  This place of Oneness is 
described as a field of pure infinite Love; the brilliant bejeweled light of Love, the 
Godhead, the Void that is a Plenum, the Creation Principle. There is a recognition of 
the unity of all and that love is the principle that organizes the universe. Smoked 5-
MeO-DMT  has been described as “ the encounter with God” experience. Of animal 
origin, the venom of the Sonoran desert toad contains 5-MeO-DMT, known to be 
toxic when consumed orally, but can be safely smoked to induce powerful 
psychoactive states (Weil, 1994; Oroc, 2009). There is ongoing archaeological research 
to trace its use to precolombian Mesoamerica. 
QEEG DMT STUDIES 
The objective of this exploratory research was to examine the objective QEEG 
correlates of the smoked inhalation of exogenous DMT experience. 
The author’s first encounter with DMT was in 2005 and motivated these 
exploratory QEEG studies conducted in Peru and Mexico. Three sources of DMT 
were tested: high purity synthetic 5-MeO- DMT, Bufo 5-MeO-DMT (an extract from 
the Sonoran desert toad venom, Bufo alvarius), and N,N- DMT from a natural extract 
of the Acacia Mimosa hostilis  root bark. A preliminary chemical analysis,(GC/MS and 
TLC) of the material used in these experiments yielded mostly 5-MeO-DMT as the 
principal alkaloid, with no detectable bufotenin (P. Daley, personal communication). 
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The DMT was delivered by smoked inhalation (vaporization). The rapid onset (10-
20 sec), short acting  (5-15 min.), and reversible nature of the effects made such a 
QEEG study feasible. DMT dosage was adjusted to elicit an effective psychedelic 
experience (ca. 20-30 mg for N,N-DMT; 2-5 mg for synthetic 5-MeO-DMT, and 30-
40 mg for the Bufo 5-MeO-DMT material). Healthy volunteers (age 25-60; N=15 men, 
N=8 women) were tested.  EEG was acquired with a Mitsar 201 amplifier (St. 
Peterburg, Russia) using 10-20 system electrocap, 19 channels referential linked ears 
montage, 250 Hz sampling rate, 0.5-40 Hz bandwidth measured.  The raw data was 
analysed with Neuroguide software (appliedneuroscience.com) after visual removal of 
ocular, muscle and movement artifacts. Qualitative comparisons were also made using 
WinEEG software. 
The protocol consisted of:  5-10 min. baseline control (resting eyes closed) was first 
acquired, followed by the DMT test condition, usually lasting 5-15 min. When subjects 
recovered from the DMT induced altered state, a report of their subjective experience 
was recorded on video and a post recovery  EEG reading was made typically at 15-30 
min. A statistical comparison (paired t-tests, correlated samples) of absolute power 
values for all EEG bands between baseline vs. DMT tests and post recovery conditions 
was carried out for all subjects. The DMT- induced profound alterations in 
consciousness  were tracked with the shifts in the QEEG metrics analysed. The time 
course and intensity of the subjective experience correlated with the magnitude of the 
observed EEG effects.  
Results. A Statistical comparison of absolute power for all bands (mean +- SEM, P 
values two-tailed) yielded, for N,N-DMT: Delta (22.19 +-3.46 vs 18.48 +-3.6, N=18, 
N.S); Theta (17.97 +-3.54 vs 10.06 +-1.05 , P<.018, N=17); Alpha (133.65 +-27.06 vs 
17.18 +-4.37, P<.0012, N=17); Beta1 (16.23+-4.16 vs 5.63+-1.9, P<.002, N=17); Beta2 
(5.26+-0.66 vs 2.73 +- 0.4, P< .0001, N=16); Beta3 (2.63 +- 0.48 vs 2.21 +0.33, P<.013, 
N=6). For High Beta increase (2.74+-0.8 vs 4.53+-1.13, P<.05, N=10). The most 
consistent effect was a robust suppression of Alpha, obtained for both N,N-DMT and 
synthetic 5-MeO-DMT (Alpha decreased ave. 72%, N=6). During recovery, some 
subjects showed Alpha rebound increased power at 15-25 min. post DMT (ave. 43% 
incr., P<.0107, N=9). A DMT induced reversible shift in FFT spectra from Alpha to 
Theta was recorded in some subjects. Also, very significant reversible hypercoherence  
in all bands (especially Beta) was measured in most subjects.  
The Bufo 5-MeO-DMT data (N=11 subjects) did not differ significantly from the 
synthetic 5-MeO-DMT findings, except the recovery time to baseline was more 
prolongued (typically 20-40 min.). Also, in most subjects a Theta peak (6-8 Hz) 
emerged during the altered state (not present in baseline EEG) which persisted 10-20 
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min. after intake and disappeared at recovery stage. Both N,N and 5-MeO-DMT 
increased Gamma power (35-40 Hz) significantly. The  Bufo 5-MeO-DMT data 
revealed increased Gamma power in 10/11 subjects tested. During post DMT Alpha 
rebound (increased power) phase, subjects reported “being in peace, a calmed  state of 
wellbeing and clarity”.   
Figures 1-4 illustrate representative results for both N,N and 5-MeO-DMT tests. 
 
 
       
  
Fig. 1 FFT power frequency spectra shows effects of N,N DMT. Baseline Alpha 
peak (ca. 10 Hz) was suppressed (ca. 75%) and a Theta peak (ca. 5.5 Hz) is now 
evidenced (*). At 20 min. post recovery, Alpha peak rebound increased ca. 190%. 
Note different power scales. 
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Fig. 2   FFT power frequency spectra shows effects of 5-MeO-DMT . 
Bufo 5-Meo-DMT induced suppression of peak Alpha ( 37% decr.) and Theta 
peak ca. 8 Hz now evidenced (*).  Recovery trend at 20 min. post was observed. 
                         
                         
  Fig. 3   5-MeO-DMT induced reversible increase in Coherence. Examples of 
Delta (1-4 Hz, top) and High Beta (25-30 Hz, bottom) hypercoherence and recovery 
at 15-20 min. post, recorded in two different subjects. 
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Fig. 4 FFT power frequency spectra shows effects on Gamma oscillations. A. 
N’N-DMT induced increase in Gamma averaged power (30-40 Hz) at 3 parietal 
sites (150% incr.) and 2 occipital (300% incr.) sites. B. Bufo 5-MeO-DMT 40 mg 
reversibly increased Gamma spectral power (38-40 Hz), shown as bar graph 
comparisons for 3 midline sites (FZ, CZ, PZ). Similar results were obtained in 
N=10/11 subjects. 
 
The magnitude of the EEG effects correlated with the time course and intensity of 
the subjective experience. The most significant EEG changes occurred in the first 2-5 
min. This is consistent with a rapid metabolic turnover of the DMT receptor binding 
mechanism of action, as demonstrated in biochemical and pharmacokinetic studies of 
the metabolic termination of DMT effects. Furthermore, the partial to full reversibility 
of the EEG effects suggest the brain is quite resilient and capable of rapid 
reorganization to baseline status. It appears that DMT action produces a reversible 
reconfiguration of network dynamics. 
The few EEG studies of Ayahuasca have reported overall suppression of power 
across many frequency bands, notably Theta, Alpha, and less consistent for low to mid 
Beta (15-25 Hz), and  increased power in High Beta band (25+ Hz) (Riba, 2002; Don, 
1998; Stuckey, 2005). A recent study reported biphasic effects: initial suppression of 
Alpha power, followed later by increased Gamma power (Ekman Schenberg et al. 
2015).  These results are in general agreement with the QEEG DMT findings reported 
by the author. 
DMT neuropharmacological mechanisms are believed to be mostly mediated via 
5-HT2A receptor binding (Nichols, 2004). However, the recent discovery of novel 
Sigma-1 receptors suggests that coactivation of serotonergic pathways and Sigma-1 
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receptor mediated cascades may be at work. A tentative hypothesis is offered 
concerning the contribution of DMT sigma-1 receptor interactions: Broadband 
desynchronization and the overall suppression of power in many EEG bands (viz. 
Theta, Alpha and low-mid Beta) reported in Ayahuasca studies and the DMT findings 
described here, may be linked to the DMT-induced inhibition of Na+ channels, which 
would effectively reduce neuronal activity and synchronization across networks in 
brain areas targeted by DMT Sigma-1 receptor binding. The increase in Hi Beta and 
Gamma power during Ayahuasca and the acute DMT tests may involve inhibition of 
the GABAergic inhibitory input to neuronal populations (eg. Pyramidal neurons) that 
generate Gamma rhythms. 
GAMMA OSCILLATIONS 
Large scale neuronal synchronization of brain networks is believed to underlie distinct 
characteristics of conscious experience. This concept of a global coordinated activation 
of patterns, “the brainweb”, was proposed in Cognitive Neuroscience (Varela et. al. 
2001). Synchronous neuronal activity in the Gamma frequency band (30-100 Hz) has 
been recorded in numerous brain regions and linked to a wide range of cognitive 
functions. Gamma oscillations have been extensively researched as EEG signature 
correlates of diverse conscious states, including visual perception, sensory processing, 
attention, learning and memory (LeBeau, 2010; Singer, 2001; Fries, 2009). Also, 
contemplative neuroscience research is revealing the roles of Gamma in higher states 
of consciousness, reporting increased Gamma power and coherence in meditative 
states (Lutz,2004) and also during Ayahuasca visionary states (Stuckey, 2005; Don et 
al., 1998; Riba et. al, 2002, Ekman Schenberg, 2015). This remarkable convergence of 
findings linked to Gamma frequency band is propelling new research directions. It is 
well established that visual processing is associated with Gamma synchronization 
across occipital brain regions (Muthukumaraswamy, 2008), and the recent studies 
linking lucid dreaming to increased occipital Gamma (Voss, 2009, 2014; Filevich et al., 
2015) are of great interest as they may shed light on the possible mechanism of 
psychedelic visionary states which closely resemble conscious dreaming states, and also 
involve increased Gamma power. The N,N-DMT QEEG findings of increased 
Gamma power are also consistent with the vision and lucid dreaming EEG data as the 
hallmark of the smoked N,N-DMT experience is characterized by a rich visionary 
experience with exquisite visual displays that  overwhelm the user with their beauty 
and strangeness. 
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THE DMN INVOLVEMENT IN MYSTICAL STATES 
 Psychedelic brain science has matured in recent years with groundbreaking findings 
on the role of the DMN in mediating the psychedelic experience. Neuroimaging fMRI 
studies of the psychedelic state induced by intravenous administration of psilocybin in 
healthy human subjects have reported reduced activation of subnetworks embedded in 
the Default Mode Network (DMN) (Carhart-Harris et al., 2011; Roseman et al. , 2014). 
This finding has been linked to the familiar ego dissolution and unity state of being 
and the experience of transcendence commonly described in the psychedelic state. 
Further evidence for the involvement of the DMN in mediating mystical states and 
meditation has been provided by studies demonstrating that the neural correlates of 
some meditation states are linked to suppression of activity in the DMN.  Subjects in 
these studies report attainment of non-dual awareness states that correlate strongly 
with reduced DMN activation at key nodes in fronto-parietal cortical sites (Brewer et 
al. , 2011; Jopovich et al., 2012, 2013 ). 
Converging evidence from a recent Brazilian fMRI study in healthy volunteers has 
also reported DMN deactivation during the Ayahuasca experience (Palhano-Fontes, F. 
et.al. ,2015). The Ayahuasca visionary experience is largely mediated by the actions of 
DMT. Thus, a neuroscience of mystical states is emerging, following from the 
pioneering  early SPECT imaging  studies of meditation that birthed the field of 
neurotheology (Newberg, 2001), and follow-up research on the spiritual brain 
(Beauregard, 2007). It is interesting to add here that subjects who have an established 
Vipassana meditation practice have reported that the Ayahuasca experience 
potentiates their meditation (personal communications). This observation is consistent 
with the reduced DMN findings abovementioned and points to the shared neural 
network mechanisms in mystical and psychedelic states. 
 CONCLUSION 
Psychedelic drugs are unique in their abilities to profoundly alter human awareness 
and perception. The neurophysiological study of psychedelic brain states is 
contributing important hints regarding the neuronal substrates of human 
consciousness and yielding clues to the nature of the Mind/Body spiritual 
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